Olezarsen Study for SHTG: This study is to check how safe and comfortable it is for people with Severe Hypertriglyceridemia (SHTG) to use a medicine called olezarsen. Hypertriglyceridemia means having very high levels of triglycerides, which are a type of fat, in the blood. This study will last for about 97 weeks in total. It includes a 31-day qualification period, a 53-week treatment period where participants will get olezarsen, and a 13-week period after the treatment ends.

To join, you must have finished either of the previous studies (ISIS 678354-CS5 or CS6) and be on a regular treatment plan for lowering fats in the blood. The study is open-label, which means both the doctors and participants know what treatment is being given. Up to 700 people can join, but if you have any new or worsening health problems, you may not be eligible to participate.

• The study lasts for almost two years.
• Participants receive treatment for 53 weeks.
• Eligibility requires a completed previous related study.